Prenetics Global (Prenetics Global) Net Margin %

: -278.87% (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Prenetics Global's Net Income for the three months ended in Sep. 2023 was $-13.6 Mil. Prenetics Global's Revenue for the three months ended in Sep. 2023 was $4.9 Mil. Therefore, Prenetics Global's net margin for the quarter that ended in Sep. 2023 was -278.87%.

The historical rank and industry rank for Prenetics Global's Net Margin % or its related term are showing as below:

PRE' s Net Margin % Range Over the Past 10 Years
Min: -218.15 Med: -66.07 Max: -2.98
Current: -15.16

PRE's Net Margin % is ranked worse than
53.98% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.145 vs PRE: -15.16

Prenetics Global Net Margin % Historical Data

The historical data trend for Prenetics Global's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Net Margin %

-218.15

-2.98

-63.08

-69.06

Prenetics Global Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Margin %									-346.87	0.61	-58.75	-382.87	-278.87

Competitive Comparison

For the Diagnostics & Research subindustry, Prenetics Global's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prenetics Global Net Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's Net Margin % distribution charts can be found below:

* The bar in red indicates where Prenetics Global's Net Margin % falls into.

Prenetics Global Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Prenetics Global's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-190.453	/	275.761
	=	-69.06 %

Prenetics Global's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin	=	Net Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-13.57	/	4.866
	=	-278.87 %

Prenetics Global (NAS:PRE) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Prenetics Global Net Margin % Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prenetics Global (Prenetics Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG

Website

https://www.prenetics.com

Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.